Expertise in
14
conditions

Nicole M. Muschol

Hamburg, HH, DE 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
14
conditions
Hamburg, HH, DE 

Overview

Nicole Muschol practices practicing medicine in Hamburg, Germany.

Ms. Muschol is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Mucopolysaccharidoses (MPS), Mucopolysaccharidosis Type 3 (MPS III, Sanfilippo Syndrome), Alpha Mannosidosis, Osteotomy, and Bone Marrow Transplant.

She is actively involved in clinical research, co-authoring 85 peer reviewed articles and participating in 9 clinical trials.

Gender

Female

Locations

Hamburg, HH, Germany
Other Locations
Eppendorf, HH, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH for Mucopolysaccharidosis (MPS) IIIA
Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH for Mucopolysaccharidosis (MPS) IIIA
Enrollment Status: Recruiting
Publish Date: August 21, 2026
Intervention Type: Drug, Biological
Study Drug: ABO-102
Study Phase: Phase 2/Phase 3
A Global, Multicenter, Single-arm, Matched External Control Study of Intrathecal SHP611 in Subjects With Late Infantile Metachromatic Leukodystrophy
A Global, Multicenter, Single-arm, Matched External Control Study of Intrathecal SHP611 in Subjects With Late Infantile Metachromatic Leukodystrophy
Enrollment Status: Completed
Publish Date: July 10, 2026
Intervention Type: Drug
Study Drug: SHP611
Study Phase: Phase 2
A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)
A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)
Enrollment Status: Completed
Publish Date: March 05, 2024
Intervention Type: Drug
A Prospective Natural History Study of Mucopolysaccharidosis Type IIIB (MPS IIIB)
A Prospective Natural History Study of Mucopolysaccharidosis Type IIIB (MPS IIIB)
Enrollment Status: Unknown
Publish Date: October 26, 2022
A Long-term Follow-up Study of Patients With MPS IIIB From Gene Therapy Clinical Trials Involving the Administration of ABO-101 (rAAV9.CMV.hNAGLU)
A Long-term Follow-up Study of Patients With MPS IIIB From Gene Therapy Clinical Trials Involving the Administration of ABO-101 (rAAV9.CMV.hNAGLU)
Enrollment Status: Terminated
Publish Date: May 31, 2022
Intervention Type: Biological
Phase I/II Gene Transfer Clinical Trial of rAAV9.CMV.hNAGLU for Mucopolysaccharidosis (MPS) IIIB
Phase I/II Gene Transfer Clinical Trial of rAAV9.CMV.hNAGLU for Mucopolysaccharidosis (MPS) IIIB
Enrollment Status: Terminated
Publish Date: May 05, 2022
Intervention Type: Biological
Study Drug: rAAV9.CMV.hNAGLU
Study Phase: Phase 1/Phase 2
An Observational, Prospective, Multi-center, Natural History Study of Patients With Mucopolysaccharidosis Type IIIA (MPS IIIA)
An Observational, Prospective, Multi-center, Natural History Study of Patients With Mucopolysaccharidosis Type IIIA (MPS IIIA)
Enrollment Status: Completed
Publish Date: August 31, 2021
Open-label, Single-arm, Multi-center Study of Intracerebral Administration of Adeno-associated Viral (AAV) Serotype rh.10 Carrying Human N-sulfoglucosamine Sulfohydrolase (SGSH) cDNA for Treatment of Mucopolysaccharidosis Type IIIA
Open-label, Single-arm, Multi-center Study of Intracerebral Administration of Adeno-associated Viral (AAV) Serotype rh.10 Carrying Human N-sulfoglucosamine Sulfohydrolase (SGSH) cDNA for Treatment of Mucopolysaccharidosis Type IIIA
Enrollment Status: Unknown
Publish Date: August 31, 2021
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
MPS VI Clinical Surveillance Program (CSP)
MPS VI Clinical Surveillance Program (CSP)
Enrollment Status: Completed
Publish Date: April 05, 2021
View 8 Less Clinical Trials

85 Total Publications

Phase 3 Randomized Trial Results of DTX401 AAV Gene Therapy for the Treatment of GSDIa.
Phase 3 Randomized Trial Results of DTX401 AAV Gene Therapy for the Treatment of GSDIa.
Journal: Journal of inherited metabolic disease
Published: April 29, 2026

Frequently Asked Questions about Nicole M. Muschol

Is Nicole M. Muschol a top-rated expert for Mucopolysaccharidoses (MPS)?

MediFind is an objective health platform that identifies experts based on real-world data. Nicole M. Muschol is classified as an Elite expert for Mucopolysaccharidoses (MPS), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Nicole M. Muschol participate in research or clinical trials?

Yes. Nicole M. Muschol has published 85 articles and abstracts on conditions like Mucopolysaccharidoses (MPS). You can view a list of Nicole M. Muschol's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Muschol's expertise for a condition
ConditionClose
View All 19 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile